COMP <GO>
CGNX vs TMO // EV/EBITDA & P/E VALUATION
Cognex Corporation (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: CGNX 6
— TMO 9
▲ EV/EBITDA & P/E VALUATION LEADER: TMO
LAST: $56.15 (-4.78%) • MKT CAP: $9.92B
valuation
58.1x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGNX VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CGNX | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.90% | 41.00% | +25.90 | CGNX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.90% | 9.30% | -0.40 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 58.1x | 30.4x | +27.70 | TMO | /valuation <GO> |
| Free Cash Flow Yield | 2.39% | 2.40% | -0.01 | TMO | /fcf-yield <GO> |
| Operating Margin | 16.30% | 17.40% | -1.10 | TMO | /operating-margins <GO> |
| Net Profit Margin | 11.50% | 15.10% | -3.60 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 8.70% | 3.90% | +4.80 | CGNX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.55% | 0.24% | +0.31 | CGNX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.69 | 4.50 | +8.19 | CGNX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | CGNX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.70% | -0.20 | CGNX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.0 | 59.1 | -15.14 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.94 | -0.06 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 80.6x | 36.3x | +44.30 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.92B | $262.22B | -$252.30B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CGNX REV | TMO REV | CGNX GROSS % | TMO GROSS % | CGNX FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $994.4M | $44.56B | 66.9% | 44.0% | $236.8M | $6.29B |
| FY 2024 | $914.5M | $42.88B | 68.4% | 44.0% | $134.0M | $7.27B |
| FY 2023 | $837.5M | $42.86B | 44.0% | 44.0% | $75.2M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGNX // BETA 0.88
TMO // BETA 0.94